Forge Biologic

EMA
#AAV #Cell and gene therapy #European Medicines Agency #Forge Biologic #Gene therapy #Priority Review

EMA prioritises AAV gene therapy for Krabbe disease

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.  PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance… Read More

#News #Regulatory